NVE (NVEC) Q2 2027 Earnings Call Transcript

NVE Corporation’s fiscal Q2 2027 revenue fell 8% year over year to $5.83 million, as product sales declined 9% amid a large medical-device customer’s inventory adjustment and a 95% drop in defense sales. Net income was $3.17 million, or $0.65 per diluted share, while first-half revenue rose 36% to $16.87 million and management expects second-half revenue to match the first half. Distributor sales increased 67% in Q2; management cited interest in new sensor products for robotics and automation and declared a $1.00-per-share quarterly dividend.

Analysis

NVEC’s key signal is the gap between a strong first-half growth rate and an uneven quarterly order pattern: the customer pull-forward shifts revenue between quarters, while the defense decline underscores that reported growth is not yet a clean read-through to end demand. Management’s second-half outlook implies a broadly stable run-rate, not accelerating growth. Distributor strength is encouraging, but can reflect channel replenishment as well as final demand; watch sell-through and inventory before treating it as durable.

The longer-term upside is real but still early-stage. Management described new robotics sensors moving from samples toward larger orders, yet did not identify customers, production schedules, or design-win economics. At the stated $1–$2 sensor ASP and “tens” of sensors per robot, content per unit is limited absent very large production volumes. The market may be capitalizing a robotics and 800-volt data-center opportunity before those volumes are evidenced. Cash generation and liquidity reduce near-term financing risk, but do not remove customer-concentration or execution risk. Lower R&D spend from staff redeployment is worth monitoring against the expanding product roadmap.

Near term, the January results are the test of management’s expected order recovery. Over 6–18 months, verified production ramps could support a broader growth profile; delays or weak conversion from samples would leave NVEC exposed to lumpy legacy demand. Abbott is an important customer, but the transcript does not quantify its revenue exposure, so there is no grounded read-through to ABT earnings. With no valuation or share-price data supplied, the print alone does not justify a directional position.

Key Decisions for Investors

• NVEC: avoid chasing the robotics narrative on this call alone. Reassess after the January report for evidence that medical-device orders normalized and that distributor growth represents sell-through rather than channel timing.
• Set a catalyst alert for Q3 results: test actual revenue against the second-half run-rate implied by guidance, product-sales recovery, and any disclosure of customer concentration or order visibility. A renewed product-sales decline or guidance reset would falsify the near-term recovery thesis.
• Treat new sensor design wins as watch items, not booked growth. Seek evidence of production-volume orders, customer ramps, and capacity utilization; delays in moving beyond samples would weaken the 6–18 month robotics upside case.
• No ABT trade: the call provides no quantified revenue exposure or evidence that NVEC supply changes would be material to Abbott.